Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan.
Department of Biomedical Engineering and.
JCI Insight. 2020 Feb 13;5(3):132880. doi: 10.1172/jci.insight.132880.
Ultrasound-induced microbubble (USMB) cavitation is widely used to promote drug delivery. Our previous study investigated USMB targeting the round window membrane by applying the ultrasound transducer to the tympanic bulla. In the present study, we further extended the use of this technology to enhance drug delivery to the inner ear by introducing the ultrasound transducer into the external auditory canal (EAC) or applying it to the skull. Using a 3-dimensional-printed diffusion apparatus mimicking the pathway for ultrasound passing through and reaching the middle ear cavity in vitro, the models simulating the transcanal and transcranial approach demonstrated 4.8-fold- and 3.7-fold-higher delivery efficiencies, respectively. In an in vivo model of guinea pigs, by filling tympanic bulla with microbubbles and biotin-FITC, USMB applied transcanally and transcranially induced 2.8-fold and 1.5-fold increases in biotin-FITC delivery efficiencies, respectively. In addition, the gentamicin uptake by cochlear and vestibular hair cells and gentamicin-induced hair cell loss were significantly enhanced following transcanal application of USMB. On the 28th day after transcanal USMB, safety assessment showed no significant changes in the hearing thresholds and the integrity of cochlea. These are the first results to our knowledge to demonstrate the feasibility and support the potential clinical application of applying USMB via EAC to facilitate drug delivery into the inner ear.
超声空化微泡(USMB)被广泛用于促进药物传递。我们之前的研究通过将超声换能器应用于耳鼓来研究针对圆窗膜的 USMB 靶向作用。在本研究中,我们通过将超声换能器引入外耳道(EAC)或应用于颅骨,进一步扩展了这项技术在增强内耳药物传递方面的应用。使用模拟超声通过并到达体外中耳腔的途径的 3D 打印扩散装置,模拟经耳道和经颅途径的模型分别显示出 4.8 倍和 3.7 倍的更高传递效率。在豚鼠的体内模型中,通过用微泡和生物素-FITC 填充耳鼓,经耳道和经颅应用 USMB 分别诱导生物素-FITC 传递效率增加了 2.8 倍和 1.5 倍。此外,经耳道应用 USMB 后,耳蜗和前庭毛细胞摄取庆大霉素和庆大霉素诱导的毛细胞损失显著增加。在经耳道 USMB 后的第 28 天,安全性评估显示听力阈值和耳蜗完整性没有显著变化。这些是我们所知的首次证明通过 EAC 应用 USMB 促进药物进入内耳的可行性和支持其潜在临床应用的结果。